David Humphreys, PhD;BSc (he/him/his)

UCB Pharma
Slough, England, United Kingdom

28 years of industrial antibody drug discovery and development, specialising in antibody engineering and production sciences.

Presentation(s):

• 0074: Rheumatoid Factors (RFs) in RA Patient Sera Do Not Bind To Fc-Free Certolizumab Pegol, But Do Bind To Fc-Containing Anti-TNF-α Biological DMARDs, Driving Immune Complex Formation and Cellular Clearance

  Sunday, October 26, 2025
  10:30 AM - 12:30 PM Central Time

  Disclosure information not submitted.